Looking for new treatments of Infantile Colic

Francesco Savino1, Simone Ceratto, Angela De Marco

  • 1Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università di Torino, Ospedale Infantile Regina Margherita - Città della Salute e della Scienza di Torino, Turin, Italy. francesco.savino@unito.it.

Insights

Infantile colic, a common infant issue, lacks clear treatment guidelines. Emerging evidence suggests dietary changes, probiotics, and certain medications may help, but more research is needed for effective management.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Microbiome Research

Background:

  • Infantile colic is a frequent, benign condition impacting families and pediatric consultations.
  • Lack of evidence-based guidelines leads to underestimation and inconsistent management by healthcare professionals.
  • Current understanding highlights the need for consensus on effective treatment strategies.

Purpose of the Study:

  • To review current evidence on various management and treatment options for infantile colic.
  • To explore the role of diet, pharmacology, complementary therapies, and behavioral interventions.
  • To highlight the emerging role of microbiota and probiotics in infantile colic.

Main Methods:

  • Literature review of dietary, pharmacological, complementary, and behavioral therapies.
  • Analysis of studies investigating specific agents like Simethicone and Cimetropium Bromide.
  • Examination of research on the role of gut microbiota and probiotic interventions.

Main Results:

  • Dietary approaches, including special formulas with prebiotics/probiotics, show promise but require further validation.
  • Simethicone may reduce bloating; Cimetropium Bromide shows potential for severe colic but needs more study.
  • Limited evidence supports complementary/behavioral therapies; probiotics are a focus, but strain-specific efficacy is unclear.

Conclusions:

  • There is no current consensus on infantile colic management, necessitating further evidence-based research.
  • Dietary modifications and novel pharmacological agents warrant continued investigation.
  • Understanding the role of microbiota is crucial for developing targeted, effective probiotic therapies for infantile colic.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
700
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
912
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
844
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
1.0K